Factors associated with postoperative acute kidney injury in stanford type a aortic dissection in china: a systematic review and meta-analysis Authors: Liping Ning, Mengling Chen, Huanhuan Luo, Peng Xie, Zuowei Li, Qiaoling Liao Published: 2026 ABSTRACT ObjectiveThis study aimed to explore the factors associated with postoperative acute kidney injury in Chinese Stanford type A aortic dissection patients through a systematic review and meta-analysis.MethodsCNKI, WanFang Database, VIP, SinoMed, PubMed, Web of Science, Embase and Cochrane Library were comprehensively searched from inception until September 2025. Two reviewers independently conducted study selection, data extraction, and quality assessment. Meta-analysis was performed using Stata 15.1 and R 4.5.0 software. The certainty of evidence was evaluated using the GRADE tool.ResultsA total of 47 eligible studies comprising 9077 patients were included. Based on these observational studies, which predominantly had low to very low certainty of evidence (GRADE), the following factors were found to be associated with postoperative AKI in Chinese Stanford type A aortic dissection patients: age[adjusted odds ratio (OR) = 1.10, 95% confidence interval (CI): 1.03–1.19, p < 0.05], BMI[OR = 1.20, 95%CI: 1.17–1.24, p < 0.001], hypertension history[OR = 2.74, 95%CI: 2.34–3.21, p < 0.001], renal artery involvement[OR = 4.40, 95%CI: 2.81–6.91, p < 0.001], preoperative cardiac tamponade[OR = 3.47, 95%CI: 1.93–6.26, p < 0.001], preoperative serum creatinine[OR = 1.16, 95%CI: 1.09–1.23, p < 0.001], preoperative platelet[OR = 0.96, 95%CI: 0.92-1.00, p < 0.05], preoperative serum myoglobin[OR = 1.69, 95%CI: 1.44–1.98, p < 0.001], preoperative serum cystatin C[OR = 6.59, 95%CI: 3.77–11.50, p < 0.001], cardiopulmonary bypass time[adjusted OR = 1.01, 95%CI: 1.00-1.02, p < 0.05], CPB > 180 min[OR = 3.48, 95%CI: 1.65–7.30, p < 0.01], operative time[OR = 1.69, 95%CI: 1.33–2.14, p < 0.05], deep hypothermic circulatory arrest time[OR = 1.16, 95%CI: 1.10–1.22, p < 0.001], aortic cross-clamp time[OR = 1.11, 95%CI: 1.01–1.21, p < 0.05], intraoperative RBCs transfusion volume[adjusted OR = 1.17, 95%CI: 1.02–1.35, p < 0.05], intraoperative urine output[OR = 0.75, 95%CI: 0.64–0.88, p < 0.001], mechanical ventilation time[OR = 1.01, 95%CI: 1.01–1.02, p < 0.001] and postoperative procalcitonin[OR = 1.03, 95%CI: 1.01–1.06, p < 0.05].ConclusionThis study demonstrates that factors associated with postoperative acute kidney injury in Chinese Stanford type A aortic dissection patients are closely related to the perioperative period. These findings may help clinicians identify risk factors early and facilitate the development of preventive strategies to improve patient outcomes.RegistrationThe research is registered on the PROSPERO website with the registration number CRD420250651792.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s13019-026-04372-7. Introduction Stanford type A aortic dissection (TAAD) represents one of the most life-threatening cardiovascular emergencies, characterized by high morbidity and mortality despite advances in surgical techniques and perioperative care [1, 2]. Postoperative acute kidney injury (AKI) has emerged as one of the most frequent and severe complications in TAAD patients [3, 4]. Previous studies have reported an incidence rate of postoperative AKI ranging from 36% to 66.7% [5], which is substantially higher than that observed in other cardiac surgery procedures [6]. Moreover, the development of postoperative AKI in TAAD surgery is associated with prolonged hospitalization, increased mortality, and a higher risk of major complications [5, 7]. To date, no proven pharmacologic interventions or targeted therapies exist for preventing or treating AKI in this setting, with renal replacement therapy (RRT) remaining the mainstay of supportive management [8]. However, the prognosis of RRT following TAAD surgery is particularly poor [9]. Consequently, early identification of reliable robust risk factors for postoperative AKI represents a critical priority for risk stratification and implementation of preventive strategies to improve clinical outcomes. China is among the countries with the highest global incidence of TAAD, with an estimated annual incidence ranging from 2.6 to 3.5 per 100,000 population [10]. Compared to Western populations, Chinese TAAD patients are often characterized by distinct demographic and clinical profiles, such as a younger age at onset, a higher prevalence of hypertension, and differences in surgical management approaches [11–13]. Furthermore, recent studies from China have reported high incidences of postoperative AKI, which may be attributed to the widespread adoption of the more sensitive KDIGO diagnostic criteria and the complexity of surgical techniques employed in Chinese centers [4]. Although Chinese researchers have explored factors associated with postoperative AKI in TAAD populations, these studies remain limited by small sample sizes, single-center designs, and substantial heterogeneity in reported risk factors. A previous meta-analysis by Wang et al. [14] that incorporated multinational data, including China, investigated risk factors for AKI after TAAD repair. However, its generalizability to Chinese patients is limited due to differences in genetic background, clinical practices, and healthcare resources. To date, no meta-analysis has systematically synthesized the factors with postoperative AKI exclusively in the Chinese TAAD surgery population. These evidentiary gaps underscore the urgent necessity for a China-focused systematic review and meta-analysis. Therefore, the present study aims to comprehensively identify and evaluate factors associated with postoperative AKI in Chinese TAAD patients. The findings are expected to provide evidence-based guidance for clinicians to develop targeted perioperative management strategies and improve clinical outcomes in this high-risk population. Methods Design This study was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [15]. The protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) and the registration number is CRD420250651792. Search strategy Eight databases were systematically searched for literature on postoperative AKI in Chinese TAAD patients from database inception to September 2025, including the China National Knowledge Infrastructure (CNKI), WanFang Database, WeiPu Database (VIP), the China Biology Medicine (CBM), PubMed, the Cochrane Library, Web of Science and Embase. In this study, we combined Medical Subject Headings (MeSH) terms with free terms to ensure a comprehensive search strategy. The search terms included the following: aortic dissection, type A aortic dissection, acute kidney injury, acute renal injury, acute renal failure, renal dysfunction, acute renal Insufficiency, acute renal trauma, predictive factor, risk factors, influence factors, relevant factors, etc. Supplementary Material 1 demonstrates the applied search strategy. Inclusion and exclusion criteria The inclusion criteria were as follows: (1) Study populations: Chinese patients aged ≥ 18 years old who undergoing surgical for TAAD. (2) Study intervention and comparators: Chinese TAAD patients with or without postoperative AKI. (3) Study outcomes: the outcome is the prediction of postoperative AKI in Chinese TAAD patients. (4) Study type: case-control studies and cohort studies that reported odds ratio (OR), relative risk (RR), or hazard ratio (HR) with 95% confidence interval (CI). (5) Language of literature: Chinese or English. (6) The literature clearly defines the diagnostic criteria for AKI, with the most widely used being the RIFLE (Risk, Injury, Failure, Loss of function, End-stage renal disease), AKIN (Acute Kidney Injury Network) and KDIGO (Kidney Disease Improving Global Outcomes). The exclusion criteria were as follows: (1) Patients who died during the operation or within 24 h after surgery. (2) Literature reviews and conference abstracts. (3) Studies with incomplete, duplicated or non-extractable data. (4) Articles for which the full text was unavailable. (5) Low-quality literature (i.e. NOS score ≤ 3 points). Data extraction and quality assessment In accordance with the predefined eligibility criteria, two reviewers (LPN and MLC) independently conducted literature searches and examinations of retrieved articles. Following perusal of titles and abstracts within Endnote 20 software, duplicate and non-pertinent records were eliminated. All information was retrieved from primary studies and archived using Microsoft Excel. The extracted dataset comprised: lead author, publication year, nation, research design category, participant count, predictor variables, effect measures (OR, RR, HR), 95% CI, AKI diagnostic criteria, outcome measures, quality rating scores, among other parameters. Two investigators (LPN and MLC) independently evaluated the methodological quality of case-control and cohort studies using the Newcastle-Ottawa Scale (NOS) [16], adhering to critical appraisal guidelines recommended by nephrology systematic reviews [17]. This instrument comprises eight items distributed across three domains—participant selection, group comparability, and outcome assessment—with a maximum attainable score of 9 points. Scores of 0–3 indicated low methodological quality, 4–6 signified moderate quality, while 7–9 denoted high quality research. The total score of more than 6 was employed to designate studies with low risk of bias. Upon completing literature screening and quality evaluation, cross-validation was implemented. Any discrepancies encountered were resolved through arbitration by a senior researcher (QLL). Statistical analysis Statistical analysis was performed using Stata 15.1 and R 4.5.0 software. The study outcomes were factors associated with postoperative AKI in Chinese TAAD patients, expressed as OR with 95% CI. Statistical heterogeneity across studies was assessed using Cochrane’s Q and I2 tests [18]. Significant heterogeneity was defined as I2 > 50% and/or P < 0.10, in which case a random-effects model was applied; otherwise, a fixed-effects model was used. The robustness of the meta-analysis results was evaluated through pooled effect estimates and sensitivity analysis using the leave-one-out method. Subgroup analysis and meta-regression were performed to identify potential sources of heterogeneity. For factors reported in five or more studies, potential publication bias was examined using funnel plots and Egger’s test. Symmetrical funnel plots and an Egger’s P > 0.05 indicated no publication bias. If asymmetry was observed, the trim-and-fill method was employed to adjust for potential bias. P < 0.05 was considered statistically significant. Certainty of evidence assessment Evidence quality was appraised using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) criterion approach [19]. This standard conducts downgrading or upgrading assessments based on prespecified criteria and classifies evidence into four grades: very low, low, moderate, and high. Five elements can downgrade evidence quality: risk of bias, imprecision, inconsistency, indirectness, and publication bias. Three elements can upgrade evidence quality: effect size, dose–response gradient, and effect of plausible residual confounding. Results Literature search results According to the search strategy, a total of 1637 articles were obtained from eight electronic databases searches, 557 duplicate articles were removed, and the remaining 143 articles were assessed for full text after screening the titles and abstracts. In the end, only 47 articles met the inclusion criteria and were included in this meta-analysis. Of the included articles, 31 cases were in the case control study, and 16 were in the cohort study. The flow diagram of the specific screening process is presented in Fig. 1. Fig. 1Flow diagram of study selection Flow diagram of study selection Characteristics and quality assessment of the included studies The 47 studies enrolling 9077 patients were included, of whom 4455 developed postoperative AKI. Among the included studies, 31 were case-control investigations and the remaining 16 were cohort studies. The articles were published between 2012 and 2025. The quality assessment of studies showed scores ranging from 6 to 9 points, and all the literature were classified as high quality. The details of research characteristics and quality assessment are shown in Table 1 and Supplementary Material 2. Table 1Characteristics and quality assessment of the included studiesAuthor/YrDesignStudy areaAKI diagnostic criteriaSample sizeOutcomesNOSAKI groupNon-AKI groupXu X, 2025Case-control studySouthKDIGO95438、228/9Zhang SQ, 2025Case-control studySouthKDIGO19616、8、157/9Zheng XZ, 2025Case-control studyNorthKDIGO1321487、87/9Li WW, 2025Case-control studySouthKDIGO84991、15、17、18、207/9Wang XH, 2025Cohort studySouthKDIGO69155238/9Yan PP, 2024Cohort studySouthKDIGO1121436、20、228/9Lei L, 2024Case-control studyNorthKDIGO47554、157/9Hu SX, 2024Case-control studySouthKDIGO223491、47/9Wu TJ, 2024Case-control studyNorthKDIGO80157197/9Liu GZ, 2024Case-control studyNorthKDIGO10286217/9Xiao WB, 2023Case-control studySouthKDIGO69429、187/9Shen XY, 2023Case-control studySouthKDIGO49365、137/9Li XS, 2023Case-control studyNorthKDIGO1472915、237/9Li DZ, 2023Case-control studySouthKDIGO17471、8、9、10、15、18、20、217/9Yu J, 2023Case-control studySouthKDIGO23681、6、8、17、247/9Wang ZG, 2023Cohort studySouthKDIGO1021201、9、169/9Guan XL, 2023Cohort studyNorthKDIGO847648/9Fang MX, 2023Cohort studySouthKDIGO3143075、6、158/9Chen YB, 2023Cohort studySouthKDIGO12413148/9Chen SW, 2023Cohort studyNorthKDIGO1532293、118/9Chen QQ, 2022Case-control studySouthKDIGO38626、8、11、157/9Yang C, 2022Case-control studyNorthKDIGO7370207/9Li SM, 2022Case-control studyNorthKDIGO931565、9、127/9Li P, 2022Case-control studyNorthKDIGO71925、7、8、9、156/9Zeng H, 2022Case-control studySouthKDIGO29101156/9Yang C, 2022Cohort studyNorthKDIGO268130118/9Wang L, 2022Cohort studySouthKDIGO2753198/9Chen WX, 2022Cohort studySouthKDIGO471121、8、148/9Guo T, 2021Case-control studySouthKDIGO61656、8、157/9Zheng QL, 2021Case-control studyNorthKDIGO352710、187/9Pan Y, 2021Case-control studySouthKDIGO682051、6、8、17、248/9Zhang YB, 2021Case-control studySouthKDIGO5166157/9Zhang K, 2021Cohort studyNorthKDIGO52813、157/9Ma XC, 2021Cohort studyNorthKDIGO1315914、157/9Liu TS, 2021Cohort studyNorthKDIGO615447/9Li XY, 2020Case-control studyNorthKDIGO46665、6、15、237/9Zong QY, 2020Cohort studySouthKDIGO5170128/9Li LJ, 2020Cohort studySouthKDIGO241944、15、207/9Xue YY, 2019Case-control studySouthKDIGO73885、76/9Su JJ, 2019Case-control studyNorthKDIGO66683、56/9Shen YW, 2019Case-control studyNorthKDIGO125512、4、8、157/9Sheng W, 2019Case-control studyNorthAKIN401808、9、157/9Xu HJ, 2019Case-control studySouthRIFLE5531076/9Zhou H, 2018Case-control studyNorthKDIGO4291241、2、4、157/9Shi HP, 2017Case-control studyNorthKDIGO453387/9Qiu ZH, 2015Cohort studySouthAKIN56991、166/9Song XR, 2012Case-control studyNorthAKIN789816/91 = Age, 2 = Body Mass Index (BMI), 3 = Hypertension history, 4 = Renal artery involvement, 5 = Preoperative cardiac tamponade, 6 = Preoperative serum creatinine (Scr), 7 = Preoperative white blood cells (WBCs), 8 = Preoperative platelet (PLT), 9 = Preoperative serum myoglobin (Mb), 10 = Preoperative serum cystatin C (sCysC), 11 = Preoperative lactate (Lac), 12 = Preoperative lymphocyte-monocyte ratio (LMR), 13 = Cardiopulmonary bypass (CPB) time, 14 = CPB time > 180 min, 15 = Operative time, 16 = Deep hypothermic circulatory arrest (DHCA) time, 17 = Aortic cross-clamp (ACC) time, 18 = Intraoperative red blood cells (RBCs) transfusion volume, 19 = Intraoperative plasma transfusion volume, 20 = Intraoperative urine output, 21 = Mechanical ventilation (MV) time, 22 = Postoperative procalcitonin (PCT). The definitions of all clinical terms are provided in Supplementary Material 3 Table 1Characteristics and quality assessment of the included studiesAuthor/YrDesignStudy areaAKI diagnostic criteriaSample sizeOutcomesNOSAKI groupNon-AKI groupXu X, 2025Case-control studySouthKDIGO95438、228/9Zhang SQ, 2025Case-control studySouthKDIGO19616、8、157/9Zheng XZ, 2025Case-control studyNorthKDIGO1321487、87/9Li WW, 2025Case-control studySouthKDIGO84991、15、17、18、207/9Wang XH, 2025Cohort studySouthKDIGO69155238/9Yan PP, 2024Cohort studySouthKDIGO1121436、20、228/9Lei L, 2024Case-control studyNorthKDIGO47554、157/9Hu SX, 2024Case-control studySouthKDIGO223491、47/9Wu TJ, 2024Case-control studyNorthKDIGO80157197/9Liu GZ, 2024Case-control studyNorthKDIGO10286217/9Xiao WB, 2023Case-control studySouthKDIGO69429、187/9Shen XY, 2023Case-control studySouthKDIGO49365、137/9Li XS, 2023Case-control studyNorthKDIGO1472915、237/9Li DZ, 2023Case-control studySouthKDIGO17471、8、9、10、15、18、20、217/9Yu J, 2023Case-control studySouthKDIGO23681、6、8、17、247/9Wang ZG, 2023Cohort studySouthKDIGO1021201、9、169/9Guan XL, 2023Cohort studyNorthKDIGO847648/9Fang MX, 2023Cohort studySouthKDIGO3143075、6、158/9Chen YB, 2023Cohort studySouthKDIGO12413148/9Chen SW, 2023Cohort studyNorthKDIGO1532293、118/9Chen QQ, 2022Case-control studySouthKDIGO38626、8、11、157/9Yang C, 2022Case-control studyNorthKDIGO7370207/9Li SM, 2022Case-control studyNorthKDIGO931565、9、127/9Li P, 2022Case-control studyNorthKDIGO71925、7、8、9、156/9Zeng H, 2022Case-control studySouthKDIGO29101156/9Yang C, 2022Cohort studyNorthKDIGO268130118/9Wang L, 2022Cohort studySouthKDIGO2753198/9Chen WX, 2022Cohort studySouthKDIGO471121、8、148/9Guo T, 2021Case-control studySouthKDIGO61656、8、157/9Zheng QL, 2021Case-control studyNorthKDIGO352710、187/9Pan Y, 2021Case-control studySouthKDIGO682051、6、8、17、248/9Zhang YB, 2021Case-control studySouthKDIGO5166157/9Zhang K, 2021Cohort studyNorthKDIGO52813、157/9Ma XC, 2021Cohort studyNorthKDIGO1315914、157/9Liu TS, 2021Cohort studyNorthKDIGO615447/9Li XY, 2020Case-control studyNorthKDIGO46665、6、15、237/9Zong QY, 2020Cohort studySouthKDIGO5170128/9Li LJ, 2020Cohort studySouthKDIGO241944、15、207/9Xue YY, 2019Case-control studySouthKDIGO73885、76/9Su JJ, 2019Case-control studyNorthKDIGO66683、56/9Shen YW, 2019Case-control studyNorthKDIGO125512、4、8、157/9Sheng W, 2019Case-control studyNorthAKIN401808、9、157/9Xu HJ, 2019Case-control studySouthRIFLE5531076/9Zhou H, 2018Case-control studyNorthKDIGO4291241、2、4、157/9Shi HP, 2017Case-control studyNorthKDIGO453387/9Qiu ZH, 2015Cohort studySouthAKIN56991、166/9Song XR, 2012Case-control studyNorthAKIN789816/91 = Age, 2 = Body Mass Index (BMI), 3 = Hypertension history, 4 = Renal artery involvement, 5 = Preoperative cardiac tamponade, 6 = Preoperative serum creatinine (Scr), 7 = Preoperative white blood cells (WBCs), 8 = Preoperative platelet (PLT), 9 = Preoperative serum myoglobin (Mb), 10 = Preoperative serum cystatin C (sCysC), 11 = Preoperative lactate (Lac), 12 = Preoperative lymphocyte-monocyte ratio (LMR), 13 = Cardiopulmonary bypass (CPB) time, 14 = CPB time > 180 min, 15 = Operative time, 16 = Deep hypothermic circulatory arrest (DHCA) time, 17 = Aortic cross-clamp (ACC) time, 18 = Intraoperative red blood cells (RBCs) transfusion volume, 19 = Intraoperative plasma transfusion volume, 20 = Intraoperative urine output, 21 = Mechanical ventilation (MV) time, 22 = Postoperative procalcitonin (PCT). The definitions of all clinical terms are provided in Supplementary Material 3 Characteristics and quality assessment of the included studies 1 = Age, 2 = Body Mass Index (BMI), 3 = Hypertension history, 4 = Renal artery involvement, 5 = Preoperative cardiac tamponade, 6 = Preoperative serum creatinine (Scr), 7 = Preoperative white blood cells (WBCs), 8 = Preoperative platelet (PLT), 9 = Preoperative serum myoglobin (Mb), 10 = Preoperative serum cystatin C (sCysC), 11 = Preoperative lactate (Lac), 12 = Preoperative lymphocyte-monocyte ratio (LMR), 13 = Cardiopulmonary bypass (CPB) time, 14 = CPB time > 180 min, 15 = Operative time, 16 = Deep hypothermic circulatory arrest (DHCA) time, 17 = Aortic cross-clamp (ACC) time, 18 = Intraoperative red blood cells (RBCs) transfusion volume, 19 = Intraoperative plasma transfusion volume, 20 = Intraoperative urine output, 21 = Mechanical ventilation (MV) time, 22 = Postoperative procalcitonin (PCT). The definitions of all clinical terms are provided in Supplementary Material 3 Results of meta-analysis A total of 22 factors were involved. There was heterogeneity in age, renal artery involvement, preoperative cardiac tamponade, preoperative Scr, preoperative WBCs, preoperative PLT, preoperative Lac, preoperative LMR, CPB time, ACC time, intraoperative RBCs transfusion volume, and intraoperative plasma transfusion volume. Therefore, a random-effects model was used for meta-analysis of these factors. The remaining factors were less heterogeneous and a fixed-effects model was used for meta-analysis. See Table 2; Fig. 2, and Supplementary Material 4. The results of meta-analysis showed that age[OR = 1.14, 95%CI: 1.07–1.21, p < 0.001], BMI[OR = 1.20, 95%CI: 1.17–1.24, p < 0.001], hypertension history[OR = 2.74, 95%CI: 2.34–3.21, p < 0.001], renal artery involvement[OR = 4.40, 95%CI: 2.81–6.91, p < 0.001], preoperative cardiac tamponade[OR = 3.47, 95%CI: 1.93–6.26, p < 0.001], preoperative Scr[OR = 1.16, 95%CI: 1.09–1.23, p < 0.001], preoperative PLT[OR = 0.96, 95%CI: 0.92–1.00, p < 0.05], preoperative serum Mb[OR = 1.69, 95%CI: 1.44–1.98, p < 0.001], preoperative sCysC[OR = 6.59, 95%CI: 3.77–11.50, p < 0.001], CPB time[OR = 1.02, 95%CI: 1.01–1.03, p < 0.001], CPB time > 180 min[OR = 3.48, 95%CI: 1.65–7.30, p < 0.05], operative time[OR = 1.69, 95%CI: 1.33–2.14, p < 0.05], DHCA time[OR = 1.16, 95%CI: 1.10–1.22, p < 0.001], ACC time[OR = 1.11, 95%CI: 1.01–1.21, p < 0.05], intraoperative RBCs transfusion volume[OR = 1.25, 95%CI: 1.10–1.42, p < 0.001], intraoperative urine output[OR = 0.75, 95%CI: 0.64–0.88, p < 0.001], MV time[OR = 1.01, 95%CI: 1.01–1.02, p < 0.001] and postoperative PCT[OR = 1.03, 95%CI: 1.01–1.06, p < 0.05] were factors associated with postoperative AKI in Chinese TAAD patients. Table 2Results of meta-analysis of factors for postoperative AKI in Chinese TAAD PatientsOutcome CategoryOutcomesStudies numberHeterogeneity testModelResults meta-analysisSensitivity analysisI2(%) P OR(95%CI) P OR(95%CI)PreoperativeAge10(20–29)71.3< 0.001RE1.14(1.07 ~ 1.21)< 0.0011.07(1.05 ~ 1.10)BMI8(21, 27, 30–35)00.451RE1.20(1.17 ~ 1.24)< 0.0011.20(1.17 ~ 1.24)Hypertension history7(36–42)28.70.209FE2.74(2.34 ~ 3.21)< 0.0012.79(2.09 ~ 3.72)Renal artery involvement8 (23, 26, 37, 40, 43–46)50.90.047RE4.40(2.81 ~ 6.91)< 0.0013.97(2.95 ~ 5.35)Preoperative cardiac tamponade4 (39, 41, 47, 48)71.40.015RE3.47(1.93 ~ 6.26)< 0.0012.92(2.46 ~ 3.46)Preoperative Scr (umol/L)13(22, 23, 25, 26, 35, 39, 43, 45–47, 49–51)98.2< 0.001RE1.16(1.09 ~ 1.23)< 0.0011.02(1.02 ~ 1.03)Preoperative WBCs (×109/L)6 (22, 24, 38, 39, 50, 52)95.0< 0.001RE1.41(0.99 ~ 2.02)0.0581.32(1.24 ~ 1.41)Preoperative PLT (×109/L)2 (22, 53)59.60.116RE0.96(0.92 ~ 1.00)0.0350.97(0.95 ~ 0.99)Preoperative serum Mb (ng/mL)3 (45, 54, 55)49.00.141FE1.69(1.44 ~ 1.98)< 0.0011.72(1.37 ~ 2.16)Preoperative sCysC (mg/L)2(38, 56)00.983FE6.59(3.77 ~ 11.50)< 0.0016.59(3.77 ~ 11.5)Preoperative Lac (mmol/L)2 (36, 57)84.30.012RE2.57(0.67 ~ 9.90)0.1701.56(1.18 ~ 2.07)Preoperative LMR2 (25, 58)70.40.066RE0.70(0.45 ~ 1.08)0.1020.79(0.68 ~ 0.92)IntraoperativeCPB time (minutes)18(20, 22, 27, 30, 34, 35, 37, 39, 40, 43, 45, 46, 50, 57–61)91.5< 0.001RE1.02(1.01 ~ 1.03)< 0.0011.01(1.01 ~ 1.01)CPB time > 180 min2 (24, 28)00.757FE3.48(1.65 ~ 7.30)0.0013.48(1.65 ~ 7.30)Operative time (hour)3(20, 23, 26)45.10.162FE1.69(1.33 ~ 2.14)0.0011.72(1.25 ~ 2.38)DHCA time (minutes)4 (20, 22, 52, 53)00.508FE1.16(1.10 ~ 1.22)< 0.0011.16(1.10 ~ 1.22)ACC time (minutes)2 (62, 63)59.80.115RE1.11(1.01 ~ 1.21)0.0251.10(1.04 ~ 1.15)Intraoperative RBCs transfusion volume (U)5(20, 22, 34, 44, 64)65.90.019RE1.25(1.10 ~ 1.42)< 0.0011.16(1.09 ~ 1.23)Intraoperative plasma transfusion volume (ml)2 (22, 65)83.90.013RE1.00(1.00 ~ 1.01)0.2531.00(1.00 ~ 1.00)Intraoperative urine output (ml/kg·h)2 (44, 49)00.868FE0.75(0.64 ~ 0.88)< 0.0010.75(0.64 ~ 0.88)PostoperativeMV time (hour)3(40, 59, 66)29.90.240FE1.01(1.01 ~ 1.02)< 0.0011.01(1.01 ~ 1.02)Postoperative PCT (ng/mL)2 (23, 26)00.841FE1.03(1.01 ~ 1.06)0.0051.03(1.01 ~ 1.06)①FE: Fixed-effects model, ②RE: Random-effects model, ③p < 0.05, p < 0.01, means statistically significant Table 2Results of meta-analysis of factors for postoperative AKI in Chinese TAAD PatientsOutcome CategoryOutcomesStudies numberHeterogeneity testModelResults meta-analysisSensitivity analysisI2(%) P OR(95%CI) P OR(95%CI)PreoperativeAge10(20–29)71.3< 0.001RE1.14(1.07 ~ 1.21)< 0.0011.07(1.05 ~ 1.10)BMI8(21, 27, 30–35)00.451RE1.20(1.17 ~ 1.24)< 0.0011.20(1.17 ~ 1.24)Hypertension history7(36–42)28.70.209FE2.74(2.34 ~ 3.21)< 0.0012.79(2.09 ~ 3.72)Renal artery involvement8 (23, 26, 37, 40, 43–46)50.90.047RE4.40(2.81 ~ 6.91)< 0.0013.97(2.95 ~ 5.35)Preoperative cardiac tamponade4 (39, 41, 47, 48)71.40.015RE3.47(1.93 ~ 6.26)< 0.0012.92(2.46 ~ 3.46)Preoperative Scr (umol/L)13(22, 23, 25, 26, 35, 39, 43, 45–47, 49–51)98.2< 0.001RE1.16(1.09 ~ 1.23)< 0.0011.02(1.02 ~ 1.03)Preoperative WBCs (×109/L)6 (22, 24, 38, 39, 50, 52)95.0< 0.001RE1.41(0.99 ~ 2.02)0.0581.32(1.24 ~ 1.41)Preoperative PLT (×109/L)2 (22, 53)59.60.116RE0.96(0.92 ~ 1.00)0.0350.97(0.95 ~ 0.99)Preoperative serum Mb (ng/mL)3 (45, 54, 55)49.00.141FE1.69(1.44 ~ 1.98)< 0.0011.72(1.37 ~ 2.16)Preoperative sCysC (mg/L)2(38, 56)00.983FE6.59(3.77 ~ 11.50)< 0.0016.59(3.77 ~ 11.5)Preoperative Lac (mmol/L)2 (36, 57)84.30.012RE2.57(0.67 ~ 9.90)0.1701.56(1.18 ~ 2.07)Preoperative LMR2 (25, 58)70.40.066RE0.70(0.45 ~ 1.08)0.1020.79(0.68 ~ 0.92)IntraoperativeCPB time (minutes)18(20, 22, 27, 30, 34, 35, 37, 39, 40, 43, 45, 46, 50, 57–61)91.5< 0.001RE1.02(1.01 ~ 1.03)< 0.0011.01(1.01 ~ 1.01)CPB time > 180 min2 (24, 28)00.757FE3.48(1.65 ~ 7.30)0.0013.48(1.65 ~ 7.30)Operative time (hour)3(20, 23, 26)45.10.162FE1.69(1.33 ~ 2.14)0.0011.72(1.25 ~ 2.38)DHCA time (minutes)4 (20, 22, 52, 53)00.508FE1.16(1.10 ~ 1.22)< 0.0011.16(1.10 ~ 1.22)ACC time (minutes)2 (62, 63)59.80.115RE1.11(1.01 ~ 1.21)0.0251.10(1.04 ~ 1.15)Intraoperative RBCs transfusion volume (U)5(20, 22, 34, 44, 64)65.90.019RE1.25(1.10 ~ 1.42)< 0.0011.16(1.09 ~ 1.23)Intraoperative plasma transfusion volume (ml)2 (22, 65)83.90.013RE1.00(1.00 ~ 1.01)0.2531.00(1.00 ~ 1.00)Intraoperative urine output (ml/kg·h)2 (44, 49)00.868FE0.75(0.64 ~ 0.88)< 0.0010.75(0.64 ~ 0.88)PostoperativeMV time (hour)3(40, 59, 66)29.90.240FE1.01(1.01 ~ 1.02)< 0.0011.01(1.01 ~ 1.02)Postoperative PCT (ng/mL)2 (23, 26)00.841FE1.03(1.01 ~ 1.06)0.0051.03(1.01 ~ 1.06)①FE: Fixed-effects model, ②RE: Random-effects model, ③p < 0.05, p < 0.01, means statistically significant Results of meta-analysis of factors for postoperative AKI in Chinese TAAD Patients ①FE: Fixed-effects model, ②RE: Random-effects model, ③p < 0.05, p < 0.01, means statistically significant Fig. 2Forest plot of the pooled effects of for postoperative AKI in Chinese TAAD Patients Forest plot of the pooled effects of for postoperative AKI in Chinese TAAD Patients Meta-regression and subgroup analysis Meta-regression analysis of factors with ≥ 10 eligible studies, using research year, study design, study region, and AKI criteria as covariates, identified research year and AKI criteria as significant source of heterogeneity for age. The same covariates were subsequently used for subgroup analyses to further investigate heterogeneity sources and assess the robustness of the identified factors. Detailed results are presented in Tables 3 and 4, and Supplementary Material 5. Table 3Meta-regression analysis of factors for postoperative AKI in Chinese TAAD PatientsFactorsIndependent variableB (95% CI)SEt P AgeResearch year−0.33(−0.59~−0.07)0.113−2.940.019Study design−0.03(−0.40 ~ 0.33)0.158−0.190.853Study region−0.27(−0.61 ~ 0.07)0.146−1.850.102AKI criteria0.48(0.02 ~ 0.95)0.2012.400.043Preoperative ScrResearch year−0.77(−1.73 ~ 0.19)0.437−1.760.105Study design−0.36(−1.89 ~ 1.17)0.696−0.510.617Study region−0.65(−1.41 ~ 0.10)0.343−1.900.084AKI criteria0.84(−1.04 ~ 2.73)0.8580.980.346CPB timeResearch year0.11(−0.26 ~ 0.49)0.1760.650.523Study design−0.15(−0.54 ~ 0.25)0.187−0.780.449Study region−0.02(−0.07 ~ 0.03)0.022−1.000.331AKI criteria0.05(−0.09 ~ 0.19)0.0650.790.442 Table 3Meta-regression analysis of factors for postoperative AKI in Chinese TAAD PatientsFactorsIndependent variableB (95% CI)SEt P AgeResearch year−0.33(−0.59~−0.07)0.113−2.940.019Study design−0.03(−0.40 ~ 0.33)0.158−0.190.853Study region−0.27(−0.61 ~ 0.07)0.146−1.850.102AKI criteria0.48(0.02 ~ 0.95)0.2012.400.043Preoperative ScrResearch year−0.77(−1.73 ~ 0.19)0.437−1.760.105Study design−0.36(−1.89 ~ 1.17)0.696−0.510.617Study region−0.65(−1.41 ~ 0.10)0.343−1.900.084AKI criteria0.84(−1.04 ~ 2.73)0.8580.980.346CPB timeResearch year0.11(−0.26 ~ 0.49)0.1760.650.523Study design−0.15(−0.54 ~ 0.25)0.187−0.780.449Study region−0.02(−0.07 ~ 0.03)0.022−1.000.331AKI criteria0.05(−0.09 ~ 0.19)0.0650.790.442 Meta-regression analysis of factors for postoperative AKI in Chinese TAAD Patients Table 4Subgroup analysis of factors for postoperative AKI in Chinese TAAD PatientsFactorsSubgroup groupingCategoryStudies numberHeterogeneity testModel95%CIEffect sizeI2(%) P Z P AgeResearch year≤ 2020353.70.115RE1.484(1.265 ~ 1.742)4.84< 0.001≥ 2021744.20.096FE1.064(1.038 ~ 1.090)4.97< 0.001Study designCase-control study767.60.005RE1.090 (1.049 ~ 1.132)4.42< 0.001Cohort study382.80.003RE1.060 (1.027 ~ 1.093)3.68< 0.001Study regionNorth200.671FE1.396 (1.177 ~ 1.655)3.83< 0.001South867.90.003RE1.066 (1.040 ~ 1.092)5.15< 0.001AKI criteriaKDIGO859.80.015RE1.068 (1.042 ~ 1.094)5.34< 0.001AKIN251.20.152RE1.792 (1.338 ~ 2.401)3.91< 0.001Renal artery involvementStudy designCase-control study631.40.200FE4.898(3.379 ~ 7.099)8.39< 0.001Cohort study271.50.061RE2.713(1.645 ~ 4.475)3.91< 0.001Preoperative cardiac tamponadeResearch year≤ 202020.00.858FE2.324(1.368 ~ 3.946)3.120.002≥ 2021289.70.002RE2.994(2.497 ~ 3.589)11.86< 0.001Study regionNorth289.70.002RE2.994(2.497 ~ 3.589)11.86< 0.001South20.00.858FE2.324(1.368 ~ 3.946)3.120.002Preoperative ScrResearch year≤ 2020393.9< 0.001RE1.025(1.010 ~ 1.039)3.400.001≥ 20211098.6< 0.001RE1.023(1.016 ~ 1.031)6.35< 0.001Study regionNorth599.4< 0.001RE1.024(1.012 ~ 1.037)3.83< 0.001South867.80.003RE1.023(1.016 ~ 1.030)6.09< 0.001Preoperative WBCsStudy regionNorth397.80.000RE1.363(1.258 ~ 1.477)7.560.000South369.50.038RE1.231(1.095 ~ 1.383)3.490.000CPB timeResearch year≤ 2020578.30.001RE1.011(1.006 ~ 1.015)4.50< 0.001≥ 20211393.3< 0.001RE1.006(1.004 ~ 1.008)6.27< 0.001Study designCase-control study1493.1< 0.001RE1.006(1.004 ~ 1.008)5.88< 0.001Cohort study472.20.013RE1.008(1.004 ~ 1.011)4.71< 0.001Study regionNorth993.1< 0.001RE1.006(1.004 ~ 1.008)5.88< 0.001South972.20.013RE1.008(1.004 ~ 1.011)4.71< 0.001Intraoperative RBCs transfusion volumeStudy designCase-control study378.90.009RE1.123(1.043 ~ 1.209)3.060.002Cohort study20.00.442FE1.217(1.104 ~ 1.341)3.95< 0.001①FE: Fixed-effects model, ②RE: Random-effects model Table 4Subgroup analysis of factors for postoperative AKI in Chinese TAAD PatientsFactorsSubgroup groupingCategoryStudies numberHeterogeneity testModel95%CIEffect sizeI2(%) P Z P AgeResearch year≤ 2020353.70.115RE1.484(1.265 ~ 1.742)4.84< 0.001≥ 2021744.20.096FE1.064(1.038 ~ 1.090)4.97< 0.001Study designCase-control study767.60.005RE1.090 (1.049 ~ 1.132)4.42< 0.001Cohort study382.80.003RE1.060 (1.027 ~ 1.093)3.68< 0.001Study regionNorth200.671FE1.396 (1.177 ~ 1.655)3.83< 0.001South867.90.003RE1.066 (1.040 ~ 1.092)5.15< 0.001AKI criteriaKDIGO859.80.015RE1.068 (1.042 ~ 1.094)5.34< 0.001AKIN251.20.152RE1.792 (1.338 ~ 2.401)3.91< 0.001Renal artery involvementStudy designCase-control study631.40.200FE4.898(3.379 ~ 7.099)8.39< 0.001Cohort study271.50.061RE2.713(1.645 ~ 4.475)3.91< 0.001Preoperative cardiac tamponadeResearch year≤ 202020.00.858FE2.324(1.368 ~ 3.946)3.120.002≥ 2021289.70.002RE2.994(2.497 ~ 3.589)11.86< 0.001Study regionNorth289.70.002RE2.994(2.497 ~ 3.589)11.86< 0.001South20.00.858FE2.324(1.368 ~ 3.946)3.120.002Preoperative ScrResearch year≤ 2020393.9< 0.001RE1.025(1.010 ~ 1.039)3.400.001≥ 20211098.6< 0.001RE1.023(1.016 ~ 1.031)6.35< 0.001Study regionNorth599.4< 0.001RE1.024(1.012 ~ 1.037)3.83< 0.001South867.80.003RE1.023(1.016 ~ 1.030)6.09< 0.001Preoperative WBCsStudy regionNorth397.80.000RE1.363(1.258 ~ 1.477)7.560.000South369.50.038RE1.231(1.095 ~ 1.383)3.490.000CPB timeResearch year≤ 2020578.30.001RE1.011(1.006 ~ 1.015)4.50< 0.001≥ 20211393.3< 0.001RE1.006(1.004 ~ 1.008)6.27< 0.001Study designCase-control study1493.1< 0.001RE1.006(1.004 ~ 1.008)5.88< 0.001Cohort study472.20.013RE1.008(1.004 ~ 1.011)4.71< 0.001Study regionNorth993.1< 0.001RE1.006(1.004 ~ 1.008)5.88< 0.001South972.20.013RE1.008(1.004 ~ 1.011)4.71< 0.001Intraoperative RBCs transfusion volumeStudy designCase-control study378.90.009RE1.123(1.043 ~ 1.209)3.060.002Cohort study20.00.442FE1.217(1.104 ~ 1.341)3.95< 0.001①FE: Fixed-effects model, ②RE: Random-effects model Subgroup analysis of factors for postoperative AKI in Chinese TAAD Patients ①FE: Fixed-effects model, ②RE: Random-effects model Sensitivity analysis The sensitivity analysis of predictive factors using random-effects and fixed-effects models showed no substantial changes for any factor, indicating robust and reliable pooled results (Table 2). For factors with I²>50% and > 2 studies, sensitivity analysis using the leave-one-out method showed markedly reduced heterogeneity for renal artery involvement, preoperative cardiac tamponade, and intraoperative RBCs transfusion volume which were subsequently analyzed using a fixed-effects model. Heterogeneity remained unchanged for other factors, which retained a random-effects model (Table 5 and Supplementary Material 6). Table 5Leave-one-out sensitivity analysisOutcomesExcluded articleBefore exclusionAfter exclusionI2(%)ModelOR(95%CI) P I2(%)ModelOR(95%CI) P AgeQiu ZH, 201571.3RE1.14(1.07 ~ 1.21)< 0.00161.0RE1.11(1.05 ~ 1.17)< 0.001Renal artery involvementYan PP, 202450.9RE4.40(2.81 ~ 6.91)< 0.00121.9FE5.08(3.57 ~ 7.23)< 0.001Preoperative cardiac tamponadeZheng XX, 202571.4RE3.47(1.93 ~ 6.26)< 0.0010FE2.79(2.34 ~ 3.31)< 0.001Preoperative ScrLi P, 202298.2RE1.16(1.09 ~ 1.23)< 0.00187.9RE1.03(1.00 ~ 1.05)0.039Preoperative WBCsLi P, 202295.0RE1.41(0.99 ~ 2.02)0.05868.6RE1.23(1.04 ~ 1.45)0.017CPB timeLi P, 202291.5RE1.02(1.01 ~ 1.03)< 0.00177.1RE1.02(1.01 ~ 1.02)< 0.001Intraoperative RBCs transfusion volumeXu F, 202365.9RE1.25(1.10 ~ 1.42)< 0.00149.8FE1.26(1.15 ~ 1.38)< 0.001 Table 5Leave-one-out sensitivity analysisOutcomesExcluded articleBefore exclusionAfter exclusionI2(%)ModelOR(95%CI) P I2(%)ModelOR(95%CI) P AgeQiu ZH, 201571.3RE1.14(1.07 ~ 1.21)< 0.00161.0RE1.11(1.05 ~ 1.17)< 0.001Renal artery involvementYan PP, 202450.9RE4.40(2.81 ~ 6.91)< 0.00121.9FE5.08(3.57 ~ 7.23)< 0.001Preoperative cardiac tamponadeZheng XX, 202571.4RE3.47(1.93 ~ 6.26)< 0.0010FE2.79(2.34 ~ 3.31)< 0.001Preoperative ScrLi P, 202298.2RE1.16(1.09 ~ 1.23)< 0.00187.9RE1.03(1.00 ~ 1.05)0.039Preoperative WBCsLi P, 202295.0RE1.41(0.99 ~ 2.02)0.05868.6RE1.23(1.04 ~ 1.45)0.017CPB timeLi P, 202291.5RE1.02(1.01 ~ 1.03)< 0.00177.1RE1.02(1.01 ~ 1.02)< 0.001Intraoperative RBCs transfusion volumeXu F, 202365.9RE1.25(1.10 ~ 1.42)< 0.00149.8FE1.26(1.15 ~ 1.38)< 0.001 Leave-one-out sensitivity analysis Publication bias Egger’s test and funnel plot were used to assess the publication bias for factors with ≥ 5 included studies. Significant publication bias was detected for age, CPB time, and intraoperative RBCs transfusion volume(p < 0.05). We performed trim-and-fill analysis to adjust for potential bias. The adjusted effect sizes were only slightly attenuated compared with the original estimates. See Table 6 and Supplementary Material 7. Table 6Results of publication biasOutcomesEgger’s TestNumber of trim-and-fillTrim-and-fill methodEffect value before trim-and-fillEffect value after trim-and-fill OR(95%CI) P Adjusted OR(95%CI) P Age0.00231.14(1.07 ~ 1.21)< 0.0011.10(1.03 ~ 1.19)0.009BMI0.601Hypertension history0.412-----Renal artery involvement0.184-----Preoperative Scr0.083-----Preoperative WBCs0.622-----CPB time< 0.00181.02(1.01 ~ 1.03)< 0.0011.01(1.00 ~ 1.02)0.027Intraoperative RBCs transfusion volume0.00221.25(1.10 ~ 1.42)< 0.0011.17(1.02 ~ 1.35)0.028Egger’s p ≥ 0.05, means no statistically significant and publication bias Table 6Results of publication biasOutcomesEgger’s TestNumber of trim-and-fillTrim-and-fill methodEffect value before trim-and-fillEffect value after trim-and-fill OR(95%CI) P Adjusted OR(95%CI) P Age0.00231.14(1.07 ~ 1.21)< 0.0011.10(1.03 ~ 1.19)0.009BMI0.601Hypertension history0.412-----Renal artery involvement0.184-----Preoperative Scr0.083-----Preoperative WBCs0.622-----CPB time< 0.00181.02(1.01 ~ 1.03)< 0.0011.01(1.00 ~ 1.02)0.027Intraoperative RBCs transfusion volume0.00221.25(1.10 ~ 1.42)< 0.0011.17(1.02 ~ 1.35)0.028Egger’s p ≥ 0.05, means no statistically significant and publication bias Results of publication bias Egger’s p ≥ 0.05, means no statistically significant and publication bias Certainty of evidence Because all the included studies were observational studies, the initial quality of the evidence is “low certainty”. After rating all evidence results, 10 were rated “very low certainty”, 10 as “low certainty” and 2 as “moderate certainty”. Table 7 provides a detailed GRADE rating of certainty around the outcome evidence. Table 7Quality of evidence of outcomesOutcomesInitial RatingDowngrading ReasonsUpgrading ReasonsCertaintyAgeLowInconsistency (−1), Publication Bias (−1)NoneVery lowBMILowNoneNoneLowHypertension historyLowNoneLarge effect (+ 1)ModerateRenal artery involvementLowNoneLarge effect (+ 1)ModeratePreoperative cardiac tamponadeLowInconsistency (−1)Large effect (+ 1)LowPreoperative ScrLowInconsistency (−2)NoneVery lowPreoperative WBCsLowInconsistency (−2), Imprecision (−1)NoneVery lowPreoperative PLTLowInconsistency (−1), Imprecision (−1)NoneVery lowPreoperative serum MbLowNoneNoneLowPreoperative sCysCLowNoneNoneLowPreoperative LacLowInconsistency (−2), Imprecision (−2)NoneVery lowPreoperative LMRLowInconsistency (−1), Imprecision (−1)NoneVery lowCPB timeLowInconsistency (−2), Publication Bias (−1)NoneVery lowCPB time > 180 minLowNoneNoneLowOperative timeLowNoneNoneLowDHCA timeLowNoneNoneLowACC timeLowInconsistency (−1)NoneVery lowIntraoperative RBCs transfusion volumeLowInconsistency (−1), Publication Bias (−1)NoneVery lowIntraoperative plasma transfusion volumeLowInconsistency (−2), Imprecision (−1)NoneVery lowIntraoperative urine outputLowNoneNoneLowMV timeLowNoneNoneLowPostoperative PCTLowNoneNoneLowThe GRADE Working Group grades evidence are as follows. High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. ①Upgraded one level for large effect size (pooled OR > 2.0) for hypertension history, renal artery involvement, and preoperative cardiac tamponade. ②Downgraded for inconsistency (substantial heterogeneity) based on I2 values: age(71.3%), preoperative cardiac tamponade(71.4%), preoperative Scr(98.2%), preoperative PLT(59.6%), preoperative Lac(84.3%), preoperative LMR(70.4%), CPB time (91.5%), ACC time(59.8%), intraoperative RBCs transfusion volume(65.9%), and intraoperative plasma transfusion volume(83.9%). ③Downgraded for publication bias based on Egger’s test: age (p = 0.005), CPB time (p < 0.001), and intraoperative RBCs transfusion volume (p = 0.002). ④Downgraded for imprecision: the 95% CI for preoperative WBCs, preoperative PLT, preoperative LMR, and intraoperative plasma transfusion volume included the null value (1.0); the 95% CI for preoperative Lac was wide Table 7Quality of evidence of outcomesOutcomesInitial RatingDowngrading ReasonsUpgrading ReasonsCertaintyAgeLowInconsistency (−1), Publication Bias (−1)NoneVery lowBMILowNoneNoneLowHypertension historyLowNoneLarge effect (+ 1)ModerateRenal artery involvementLowNoneLarge effect (+ 1)ModeratePreoperative cardiac tamponadeLowInconsistency (−1)Large effect (+ 1)LowPreoperative ScrLowInconsistency (−2)NoneVery lowPreoperative WBCsLowInconsistency (−2), Imprecision (−1)NoneVery lowPreoperative PLTLowInconsistency (−1), Imprecision (−1)NoneVery lowPreoperative serum MbLowNoneNoneLowPreoperative sCysCLowNoneNoneLowPreoperative LacLowInconsistency (−2), Imprecision (−2)NoneVery lowPreoperative LMRLowInconsistency (−1), Imprecision (−1)NoneVery lowCPB timeLowInconsistency (−2), Publication Bias (−1)NoneVery lowCPB time > 180 minLowNoneNoneLowOperative timeLowNoneNoneLowDHCA timeLowNoneNoneLowACC timeLowInconsistency (−1)NoneVery lowIntraoperative RBCs transfusion volumeLowInconsistency (−1), Publication Bias (−1)NoneVery lowIntraoperative plasma transfusion volumeLowInconsistency (−2), Imprecision (−1)NoneVery lowIntraoperative urine outputLowNoneNoneLowMV timeLowNoneNoneLowPostoperative PCTLowNoneNoneLowThe GRADE Working Group grades evidence are as follows. High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. ①Upgraded one level for large effect size (pooled OR > 2.0) for hypertension history, renal artery involvement, and preoperative cardiac tamponade. ②Downgraded for inconsistency (substantial heterogeneity) based on I2 values: age(71.3%), preoperative cardiac tamponade(71.4%), preoperative Scr(98.2%), preoperative PLT(59.6%), preoperative Lac(84.3%), preoperative LMR(70.4%), CPB time (91.5%), ACC time(59.8%), intraoperative RBCs transfusion volume(65.9%), and intraoperative plasma transfusion volume(83.9%). ③Downgraded for publication bias based on Egger’s test: age (p = 0.005), CPB time (p < 0.001), and intraoperative RBCs transfusion volume (p = 0.002). ④Downgraded for imprecision: the 95% CI for preoperative WBCs, preoperative PLT, preoperative LMR, and intraoperative plasma transfusion volume included the null value (1.0); the 95% CI for preoperative Lac was wide Quality of evidence of outcomes The GRADE Working Group grades evidence are as follows. High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. ①Upgraded one level for large effect size (pooled OR > 2.0) for hypertension history, renal artery involvement, and preoperative cardiac tamponade. ②Downgraded for inconsistency (substantial heterogeneity) based on I2 values: age(71.3%), preoperative cardiac tamponade(71.4%), preoperative Scr(98.2%), preoperative PLT(59.6%), preoperative Lac(84.3%), preoperative LMR(70.4%), CPB time (91.5%), ACC time(59.8%), intraoperative RBCs transfusion volume(65.9%), and intraoperative plasma transfusion volume(83.9%). ③Downgraded for publication bias based on Egger’s test: age (p = 0.005), CPB time (p < 0.001), and intraoperative RBCs transfusion volume (p = 0.002). ④Downgraded for imprecision: the 95% CI for preoperative WBCs, preoperative PLT, preoperative LMR, and intraoperative plasma transfusion volume included the null value (1.0); the 95% CI for preoperative Lac was wide Discussion In summary, this meta-analysis suggests several preoperative, intraoperative, and postoperative factors that may be associated with postoperative AKI in Chinese TAAD patients. According to the GRADE assessment, the certainty of evidence was rated as very low for 10 outcomes, low for 10 outcomes, and moderate for only 2 outcomes. Given that most evidence is of low to very low certainty and all included studies are observational, these findings should be interpreted with caution. Preoperative factors This study found that the following preoperative factors were potentially associated with postoperative AKI in Chinese TAAD patients: age, BMI, history of hypertension, renal artery involvement, preoperative cardiac tamponade, preoperative Scr, preoperative PLT, preoperative serum Mb, and preoperative sCysC. In this study, advanced age was found to be associated with postoperative AKI among Chinese TAAD patients, a finding that is consistent with the meta-analysis conducted by Wang et al.[14]. Previous studies have reported that for every 10-year increase in patient age, the risk of AKI after TAAD surgery increases by 1.3 to 1.37 times [3, 67]. On the one hand, renal function gradually declines with advancing age, manifested as decreased glomerular filtration rate, diminished renal reserve capacity, and altered tubular function [68]. On the other hand, elderly patients with AKI tend to have higher hospitalization rates, are more susceptible to comorbidities, and face a greater risk of progression to chronic kidney disease [69]. Therefore, this discovery suggests that renal function monitoring and protection in elderly patients following TAAD surgery could be considered. Elevated BMI was found to be potentially associated with increased AKI risk, which is consistent with previous meta-analyses [14]. The association between obesity and postoperative AKI is multifactorial. First, obesity induces specific renal changes, namely obesity-related glomerulopathy, characterized by increased glomerular filtration rate, elevated renal blood flow, and glomerular hypertrophy [70]. These changes increase glomerular stress and reduce functional nephron reserve. Furthermore, inflammatory cytokines released from adipose tissue promote systemic oxidative stress, compounding renal injury during CPB [71, 72]. Additionally, obesity frequently coincides with comorbidities such as hypertension and diabetes, which themselves predispose patients to renal hypoperfusion. Therefore, it is necessary to recommend closer postoperative renal monitoring for obese Chinese TAAD patients. Hypertension history was noted as a factor potentially associated with postoperative AKI in Chinese TAAD patients. Chronic hypertension causes glomerular hyperperfusion and structural damage, diminishing renal functional reserve [73]. When superimposed on the surgical trauma, inflammation, and ischemia-reperfusion injury of TAAD repair [74], this compromised reserve significantly elevates AKI risk. Preoperative cardiac tamponade may be a factor potentially associated with postoperative AKI in Chinese TAAD patients. By compressing the heart and impairing function, it reduces cardiac output and renal perfusion [75]. It can also cause venous congestion and elevated central venous pressure, exacerbating renal venous outflow obstruction [76]. Urgent intervention—pericardiocentesis and prompt surgical repair—is crucial to mitigate renal ischemia. Elevated preoperative Scr, elevated sCysC, and renal artery involvement were each found to be potentially associated with postoperative AKI in Chinese TAAD patients, which is consistent with earlier reports [77, 78]. As a traditional marker of renal function, elevated preoperative Scr indicates underlying renal insufficiency or decreased compensatory reserve. In recent years, novel biomarkers for renal assessment have gained increasing attention [79]. CysC—a cysteine protease inhibitor produced by all nucleated cells—has been established as a reliable estimator of glomerular filtration rate [80]. It demonstrates clinical superiority over creatinine by rising 1–2 days earlier, thereby offering earlier diagnostic value for AKI [81, 82]. Although sCysC effectively predicts AKI, its diagnostic threshold requires standardization [83]. Furthermore, renal artery involvement promotes false lumen expansion, causing renal ischemia that activates neurohormonal pathways and oxidative stress, culminating in AKI [84]. Thus, patients with renal artery involvement require close monitoring, hemodynamic optimization, and prompt intervention. Future studies should establish an optimal sCysC cutoff and integrate it into predictive models for TAAD-associated AKI. Preoperative PLT might be related to postoperative AKI risk in Chinese TAAD patients, although the literature presents divergent conclusions [85]. The pathophysiological link may involve the role of platelets in inflammation and ischemia-reperfusion injury, potentially exacerbating renal damage [86]. Elevated preoperative Mb was observed to be possibly associated with postoperative AKI in Chinese TAAD patients, consistent with prior reports [87]. Mb, an oxygen-binding protein in muscle, is normally cleared renally [88]. During TAAD surgery, hypoperfusion and surgical trauma induce muscle ischemia, triggering its release into circulation [89]. Mb accumulation in renal tubules exerts direct cytotoxic and obstructive effects on tubular epithelial cells, leading to AKI [90]. This is supported by studies linking Mb to AKI in other cardiac surgeries [91]. Notably, aortic procedures cause greater muscle injury than routine cardiac operations [92], highlighting rhabdomyolysis as a distinct pathway for AKI in TAAD. Thus, preoperative Mb serves as a practical biomarker for early risk stratification and intervention. Intraoperative factors This meta-analysis suggests that operative time, CPB time, ACC time, and DHCA time may be associated with the development of postoperative AKI in Chinese TAAD patients. Notably, CPB duration exceeding 180 min significantly elevates AKI risk (OR = 3.48), aligning with prior reports [14, 77]. The inherent complexity of TAAD repair—requiring aortic reconstruction, myocardial protection, and cerebral preservation—often extends operative time, which in turn prolongs anesthesia, tissue exposure, fluid shifts, and blood loss, collectively intensifying systemic stress and metabolic disturbance. CPB induces non-physiological perfusion, leading to renal hypoperfusion, hemolysis, glomerular barrier impairment, and activation of the renin–angiotensin–aldosterone system, all contributing to AKI [93]. It also promotes hemodynamic instability and systemic oxidative stress, exacerbating renal ischemia–reperfusion injury [94]. ACC time correlates strongly with both operative and CPB duration; during clamping, blood–circuit interaction activates complement and inflammatory mediators, causing renal edema [95], while subsequent reperfusion further aggravates inflammatory injury. During DHCA, renal arterial flow ceases completely. Longer arrest time progressively increases the risk of acute tubular necrosis, inflammation, apoptosis, and epithelial cell death [96]. Each 5-minute increase in renal ischemia time raises AKI risk by approximately 16% [97]. Therefore, refining surgical and perfusion strategies to minimize these time parameters—tailored to the patient’s condition and dissection extent—is essential to reduce AKI incidence. Intraoperative RBCs transfusion volume may be associated with postoperative AKI in Chinese TAAD patients, a finding similar to previous reports [98, 99]. Transfusion can trigger systemic inflammation and exacerbate oxidative stress [100]. Moreover, stored RBCs undergo progressive morphological changes and hemolysis, leading to the accumulation of nephrotoxic free hemoglobin and iron [101]. Additionally, the altered membrane integrity of older stored RBCs increases their susceptibility to intravascular hemolysis post-transfusion; the resulting degradation products can mechanically obstruct renal tubules, impair filtration, and increase renal workload, collectively promoting AKI [102]. Therefore, adopting a restrictive transfusion strategy may help mitigate the risk of AKI following surgery. Higher intraoperative urine output may be a protective factor against postoperative AKI in Chinese TAAD patients, and a decrease of 1 ml/(kg·h) was associated with an approximately 33% higher risk in this analysis. As a real-time marker of renal perfusion and filtration, urine output reflects glomerular filtration rate and tubular function. During TAAD surgery, however, its interpretation is complicated by CPB. While factors such as hemodilution, hypothermia, and diuretic administration may increase urine volume, CPB-induced non-pulsatile flow, systemic inflammation, and hemolysis can impair microcirculatory and endothelial function, reducing renal blood flow and filtration [103, 104]. Although no consensus threshold defines intraoperative oliguria in cardiac surgery, studies suggest that outputs below 3.70–4.00 ml/(kg·h) during CPB may help stratify AKI risk [105, 106]. These findings, however, derive from single-center retrospective analyses, highlighting the need for large, prospective multicenter studies to establish a standardized, clinically applicable urinary output threshold for AKI prediction in TAAD surgery. Postoperative factors This study suggests that MV time and postoperative PCT could be potential correlates of postoperative AKI in Chinese TAAD patients. Prolonged MV might be related to AKI risk in Chinese TAAD patients, consistent with prior reports [77]. Extended ventilation not only reflects underlying lung injury but can also directly impair renal perfusion by elevating intrathoracic pressure, reducing venous return and cardiac output [107]. Moreover, it may exacerbate systemic inflammation and apoptotic pathways, further predisposing to renal injury [108]. Thus, strategies to shorten ventilation time—through improved lung protection, early mobilization, and proactive weaning—could help lower AKI incidence. Elevated postoperative PCT may also be associated with postoperative AKI in Chinese TAAD patients. As a sensitive marker of systemic inflammation, PCT promotes renal microvascular inflammation, neutrophil activation, and oxidative stress, collectively aggravating kidney damage [108]. Dynamic perioperative monitoring of PCT may therefore aid in early risk stratification and guide timely intervention in high-risk TAAD patients. Sources of heterogeneity Meta-regression analysis revealed that research year and AKI criteria were significant sources of heterogeneity in the association between advanced age and postoperative AKI. The negative coefficient for research year indicated that the effect of age on AKI risk diminished over time, which may be attributable to continuous improvements in surgical techniques and perioperative management strategies in recent years. The positive coefficient for AKI diagnostic criteria suggested that studies employing different AKI definitions yielded varying effect estimates for age; more sensitive criteria (e.g., KDIGO) may capture a broader spectrum of mild AKI cases, thereby amplifying age-related risk. Subgroup analyses further revealed that research year, study region, and AKI criteria may be sources of heterogeneity in the effect sizes of certain factors. The effect of age was more pronounced in studies published before 2020, those conducted in northern regions, and those using AKIN criteria, corroborating the meta-regression findings. Renal artery involvement demonstrated a larger effect size in case-control studies than in cohort studies, suggesting that study design may have influenced the accuracy of effect estimation. Additionally, high residual heterogeneity persisted across subgroups for preoperative Scr and CPB time, indicating the presence of unidentified confounders; thus, these results should be interpreted cautiously. Future studies should standardize AKI diagnostic criteria and prioritize prospective cohort designs to more accurately evaluate the predictive value of these factors. Limitations and strengths of this study This review has some limitations, so the results of the meta-analysis should be interpreted with caution. Firstly, the meta-analysis for some factors included a limited number of studies (≤ 2), while other factors exhibited substantial heterogeneity. Although sensitivity analysis, meta-regression, and subgroup analysis were performed to explore the heterogeneity, the sources of heterogeneity could not be fully elucidated. Secondly, according to GRADE criteria, among all 22 outcome measures, 10 were rated as having very low certainty of evidence, 10 as low certainty, and only 2 as moderate certainty. as they may be affected by inter-study inconsistency, publication bias, and imprecision. Finally, all included studies were conducted in Chinese populations, and the conclusions drawn may not be generalizable to other countries. The management of TAAD surgery varies internationally, which may further limit the external validity of our findings. Given these limitations, the findings should be interpreted with caution and considered hypothesis-generating. Future research should involve multinational, prospective, high-quality studies with standardized data reporting to reduce heterogeneity and thereby enhance the reliability of conclusions. Despite methodological limitations, this study possesses notable strengths: (1) The included literature was of high quality, with NOS scores exceeding 6 points and appropriately screened journal sources (2) Data were extracted from multivariate regression analyses rather than univariate results, thereby partially mitigating confounding effects and enhancing reliability. Summary This meta-analysis suggested perioperative factors associated with postoperative AKI in Chinese TAAD patients, but the certainty of evidence varied across these factors. GRADE assessment indicated that most factors were rated as low to very low certainty. Therefore, these findings should be regarded as exploratory and are insufficient to directly guide clinical decision-making. Nevertheless, this study suggests that optimized perioperative management may help reduce the risk of postoperative AKI and provides a reference for early identification of high-risk populations and targeted preventive strategies. These conclusions require further validation through high-quality prospective studies before they can be applied in clinical practice. Supplementary Information Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2. Supplementary Material 3. Supplementary Material 3. Supplementary Material 4. Supplementary Material 4. Supplementary Material 5. Supplementary Material 5. Supplementary Material 6. Supplementary Material 6. Supplementary Material 7. Supplementary Material 7.